Johnson & Johnson Aktie
WKN: 853260 / ISIN: US4781601046
|
16.07.2025 13:01:20
|
Johnson & Johnson Q2 Profit Increases, Beats Estimates
(RTTNews) - Johnson & Johnson (JNJ) announced a profit for its second quarter that Increased from the same period last year and beat the Street estimates.
The company's earnings totaled $5.537 billion, or $2.29 per share. This compares with $4.686 billion, or $1.93 per share, last year.
Excluding items, Johnson & Johnson reported adjusted earnings of $6.699 billion or $2.77 per share for the period.
Analysts on average had expected the company to earn $2.68 per share. Analysts' estimates typically exclude special items.
The company's revenue for the period rose 5.8% to $23.743 billion from $22.447 billion last year.
Johnson & Johnson earnings at a glance (GAAP) :
-Earnings: $5.537 Bln. vs. $4.686 Bln. last year. -EPS: $2.29 vs. $1.93 last year. -Revenue: $23.743 Bln vs. $22.447 Bln last year.
Looking ahead, citing strong operational performance and favorable foreign exchange, Johnson & Johnson has revised up its annual outlook.
The company now expects annual adjusted income per share of $10.80 to $10.90, higher than the earlier outlook of $10.50 to $10.70 per share. This revised outlook reflects a year-on-year growth of 8.2% to 9.2%.
For the full year, adjusted operational income per share is now projected to be $10.63 to $10.73 as against the earlier guidance of $10.50 to $10.70 per share. This revised guidance reflects a growth of 6.5% to 7.5% from last year.
JNJ now projects full-year reported sales of $93.2 billion to $93.6 billion, compared with the prior expectation of $91 billion to $91.8 billion. This revised guidance reflects a growth of 5.1% to 5.6% from last year.
Analysts, on average, forecast the company to report income of $10.61 per share on revenue of $91.33 billion for the full year.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnson
|
07.10.26 |
Schwacher Handel in New York: Dow Jones zum Handelsende im Minus (finanzen.at) | |
|
07.10.26 |
Dow Jones-Handel aktuell: Dow Jones in der Verlustzone (finanzen.at) | |
|
07.10.26 |
NYSE-Handel So performt der Dow Jones aktuell (finanzen.at) | |
|
07.10.26 |
Schwacher Handel in New York: Dow Jones liegt zum Start im Minus (finanzen.at) | |
|
05.10.26 |
Börse New York: Dow Jones zum Ende des Montagshandels mit Gewinnen (finanzen.at) | |
|
05.10.26 |
Gewinne in New York: Dow Jones nachmittags mit Zuschlägen (finanzen.at) | |
|
05.10.26 |
Schwacher Handel in New York: Dow Jones verliert (finanzen.at) | |
|
02.10.26 |
Dow Jones aktuell: Dow Jones klettert zum Handelsende (finanzen.at) |
Analysen zu Johnson & Johnson
Aktien in diesem Artikel
| Johnson & Johnson | 231,10 | 2,21% |
|